<DOC>
	<DOCNO>NCT02037282</DOCNO>
	<brief_summary>Despite currently available antiviral , influenza cause significant morbidity mortality , 226,000 excess hospitalization 30,000-50,000 death year United States alone , therapy need armamentarium anti-influenza medication include humoral immunity-based agent . This study evaluate pharmacokinetics anti-influenza hyperimmune intravenous immunoglobulin . Beginning low dose , subject receive anti-influenza intravenous immunoglobulin ( FLU-IVIG ) evaluate Study Days 0 , 3 , 7 , 14 , 28 . The safety tolerability evaluate use symptom , clinical laboratory test , pharmacokinetics . Utilizing serum antibody response determine hemagglutination inhibition ( HAI ) assay , dose escalate immunogenicity establish .</brief_summary>
	<brief_title>A Phase 1 , Open Label , Ascending Dose Cohort Study Pharmacokinetics Anti-Influenza Hyperimmune Intravenous Immunoglobulin Healthy Subjects</brief_title>
	<detailed_description>Despite currently available antiviral , influenza cause significant morbidity mortality , 226,000 excess hospitalization 30,000-50,000 death year United States alone , therapy need armamentarium anti-influenza medication include humoral immunity-based agent . This study evaluate pharmacokinetics anti-influenza hyperimmune intravenous immunoglobulin . Beginning low dose , subject receive anti-influenza intravenous immunoglobulin ( FLU-IVIG ) evaluate Study Days 0 , 3 , 7 , 14 , 28 . The safety tolerability evaluate use symptom , clinical laboratory test , pharmacokinetics . Utilizing serum antibody response determine hemagglutination inhibition ( HAI ) assay , dose escalate immunogenicity establish .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age great equal 18 year less equal 50 year 2 . Weight le equal 100 kg 3 . Patients must willing forgo seasonal influenza vaccine 28 day , MMR varicella vaccine 3 month post infusion study drug 4 . Females able become pregnant ( i.e. , postmenopausal , undergone surgical sterilization , sexually active men ) must agree use least 1 effective form contraception date subject signing informed consent form 28 day dose study drug EXCLUSION CRIATERIA : 1 . Any chronic medical problem require daily oral medication ( except Tylenol , oral contraceptive , vitamin , seasonal allergy medication ) , medical history opinion investigator significantly increase risk associate IVIG 2 . Women breastfeed 3 . Positive urine serum pregnancy test 4 . Known sensitivity IVIG 5 . IgA &lt; 7 mg/dL 6 . Influenza HAI H1N1 &gt; 1:20 7 . Receipt vaccination within 30 day prior study drug administration 8 . Preexisting condition associate increase risk thrombosis cryoglobulinemia , hypertriglyceridemia , monoclonal gammopathy 9 . Estimated glomerular filtration rate ( GFR ) &lt; 60 mL/min screening , calculate use MDRD formula 10 . Medical condition receipt 750 mL volume may dangerous patient ( e.g. , decompensated congestive heart failure ) 11 . Abnormal chemistry panel Defined clinically significant baseline Grade 1 great toxicity , Grade 3 great toxicity ( regardless clinical significance ) toxicity table Evaluating total CO2 ( bicarbonate ) , creatinine , alkaline phosphatase , ALT , AST , total bilirubin , estimate GFR MDRD equation 12 . Abnormal complete blood count ( CBC ) Defined clinically significant baseline Grade 1 great toxicity , Grade 3 great toxicity ( regardless clinical significance ) toxicity table Evaluating WBC , hemoglobin , hematocrit , platelets 13 . Positive serology Hepatitis B surface antigen 14 . Positive serology Hepatitis C 15 . Positive serology HIV1 16 . Prior treatment investigational drug therapy within 5 halflives 30 day , whichever longer , prior study drug administration ( i.e. , Day 0 ) 17 . Receipt blood product 30 day prior study drug administration ( i.e. , Day 0 ) 28 day dose study drug 18 . Presence preexist illness , opinion investigator , would place patient unreasonably increase risk participation study 19 . Patients , judgment investigator , unlikely comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2, 2014</verification_date>
	<keyword>HAI Titer</keyword>
	<keyword>Hemagglutination Inhibition Assays</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Serum Antibody Response</keyword>
</DOC>